title: Breast cancer risk assessment, prevention, and the future.
abstract: Today breast cancer remains a major public health problem, although reducing its risk is now an achievable medical objective. Risk-assessment models may be used in estimating a woman's risk for developing breast cancer and to direct suitable candidates for preventive therapy. Researchers are attempting to enhance individualized risk assessment through incorporation of phenotypic biomarkers. Individual selective estrogen receptor modulators have been approved for breast cancer risk reduction, and other drug categories are being studied. It is critical that obstetrician-gynecologists be familiar with the evolving science of the risk assessment of breast cancer as well as interventional and surveillance strategies.
authors.affiliation: Department of Obstetrics and Gynecology, Gynecology Breast Clinic, Avon Comprehensive Breast Center, Winship Cancer Institute, Emory University at Grady Memorial Hospital, 69 Jesse Hill Jr Drive, Atlanta, GA 30303, USA. Electronic address: vgree01@emory.edu.
authors.forename: Victoria L
authors.initials: VL
authors.lastname: Green
mesh_terms: D001943:Breast Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000517:prevention & control*; D005260:Female; D006801:Humans; D015233:Models, Statistical; D018570:Risk Assessment; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use
chemical_list: D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen
keywords: Breast cancer risk assessment; Chemoprevention; Nipple aspirate fluid; Preventive therapy; Random periareolar fine-needle aspiration; Risk models